Trial Profile
Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From ≥1 Month to <16 Years Old With Epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 May 2022
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors UCB
- 26 Apr 2022 Interim results of post-hoc pooled analysis assessing cognitive/behavioral effects and tolerability of long-term adjunctive brivaracetam (BRV) in children/adolescents with focal seizures (N01263/NCT00422422 & N01266/NCT01364597) presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 24 Jun 2020 According to a UCB media release, interim subgroup analysis of pooled data from (NCT00422422 and NCT01364597) published in the online supplement to Neurology
- 24 Jun 2020 According to a UCB media release, interim subgroup analysis of pooled data from (NCT00422422 and NCT01364597) available online via the 2020 AAN Science Highlights virtual platform.